Pfizer (PFE) has entered into three settlement agreements for VYNDAMAX. As a result of this settlement, revenues are now expected to remain relatively stable from 2028 through mid-2031.

Pfizer's settlement agreements for VYNDAMAX, involving Dexcel Pharma, Hikma Pharmaceuticals, and Cipla, signify a strategic move to stabilize future revenues through 2031.

Newsquawk StaffPublished On the live feed at 7 more headlines followed before this page went public
Newsquawk headlinesUTC

BCB's Teizeria to miss the April meeting

FedEx (FDX) says if tariff refunds are awarded to the Co., then they will issue the necessary refunds to customers

Pfizer (PFE) has entered into three settlement agreements for VYNDAMAX. As a result of this settlement, revenues are now expected to remain relatively stable from 2028 through mid-2031.

Nucor (NUE) says that steel products margin compression from higher steel input costs should ease as the year progresses, as realised pricing catches up

Sherwin-Williams (SHW) says it expects to see inflating costs impacting materially through Q2 and into the second half of the year

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Deals with: Dexcel Pharma, Hikma Pharmaceuticals (HIK LN) and Cipla (CIPLA)
Context

This consistency in revenue expectations may bolster investor confidence and influence analysts' outlooks on Pfizer's performance in the pharmaceutical space, particularly in the EU and US markets.

Related headlines

The whole workspace, free to try.

Try it free